Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single-dose oral L-DOPS 300 mg in environmental exposure unit for seasonal allergic rhinitis
2004-002708-13Phase 2Completed
- Sponsor
- Synergia Pharma, Inc.
- Start
- May 2005
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of droxidopa in seasonal allergic rhinitis (SAR) (2 arms), sponsored by Synergia Pharma, Inc. Primary endpoints: Effect of single 300 mg dose of L-DOPS on nasal congestion, Effect on overall nasal symptoms and 2 more. Started May 2005; status: completed.
02
Drugs
droxidopa
03
Conditions
seasonal allergic rhinitis (SAR)
Beyond the preview
Go deeper on 2004-002708-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-002708-13.